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A B S T R A C T
The prevalence of life habits may vary substantially within a country. Incidence maps of strongly related
diseases can illustrate the distribution of these life style habits. In this study we explored the spatial
variation in Belgium for different cancers related to alcohol and/or tobacco.
From the Belgian Cancer Registry, municipality speciﬁc World Standardised incidence rates for the
years 2004–2011 are used to create detailed smoothed cancer maps by subsite or histology for cancers of
oral cavity, pharynx, larynx, oesophagus, liver and lung. Cancer incidence is compared both visually
(from incidence maps) and with Poisson regression analysis using mortality from chronic liver disease
and chronic obstructive pulmonary disease as a proxy for alcohol and tobacco prevalence, respectively.
The incidence rates for oral cavity, pharyngeal and laryngeal cancer were comparable with the alcohol
gradient. However, glottic cancer revealed a pattern that was more comparable with lung cancer. These
two tumour types resembled more closely to the smoking pattern. Oesophageal cancer showed two
patterns: squamous cell carcinoma was highly comparable with the background alcohol consumption,
while adenocarcinoma was unrelated to one of our two proxies.
Our approach and results are an encouraging example how data from a young cancer registry can be
used in studies describing the regional cancer burden. The results can be useful for primary prevention to
increase awareness for the public, authorities and health care professionals in speciﬁc subpopulations.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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jou r nal h o mep age: w ww.c an cer ep idem io log y.n et1. Introduction
Cancer registration in Belgium has evolved from a number of
regional initiatives in the late nineties towards a national and
centralised population based cancer registry. Nationwide data are
being collected since the incidence year 2004. In addition to
describing cancer patterns and trends in incidence and survival
[1–4], the Belgian Cancer Registry (BCR) is involved in (prospec-
tive) clinical registration projects, in the evaluation of quality of
care in oncology and in the registration for all cyto-histological
specimens taken for early diagnosis and screening for breast,
colorectal and cervical cancer.
The aim of this study – which is one of the ﬁrst peer-reviewed
articles to come out from the BCR – is to demonstrate possibilities
to perform ecological analyses in a young population based cancer* Corresponding author at: Belgian Cancer Registry, Koningsstraat 215/7,
1210 Brussel, Belgium. Tel.: +32 2 2501010.
E-mail address: Kris.Henau@kankerregister.org (K. Henau).
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3.0/).registry that has not yet acquired historical time series of cancer
data. Our objective was to visualise the spatial variation in Belgium
for different cancers with a well-known relation to alcohol and/or
tobacco. A further aim is to reveal patterns of speciﬁc subsites or
histological subtypes of cancers for which there is only limited
evidence of an association with alcohol and tobacco consumption.
Smoking and drinking habits may vary substantially within a
country. In such a case, there should be a clear spatial variation in
incidence of diseases strongly related to the use of alcohol and
tobacco. To our knowledge no data are available on drinking
or smoking prevalence neither on municipality level nor on an
individual level that would allow calculation of prevalence rates
for any regional unit in Belgium. Search for data for small regions is
further complicated due to strict privacy regulations. The only data
on the regional drinking patterns in Belgium are available from the
National Health Surveys which is based on small number of
participants [5]. Therefore, the only option to get information on
spatial distribution is to rely on proxy variables on the drinking and
smoking habits in Belgium. For this study, we used mortality rates
for chronic liver disease (CLD) and chronic obstructive pulmonarye under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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use, respectively.
2. Patients and methods
2.1. Data sources
Belgium, a nation covering an area of 30,528 square kilometres
and a population of about 11 million people, is situated in Western
Europe in between the Netherlands to the north-northeast,
Germany and Luxembourg to the east, France to the south and
southwest, and the North Sea to the west.
The BCR is a national population based cancer registry,
collecting data on the national level since the incidence year
2004. The speciﬁc Cancer Registration Law of December 13th 2006
[6] authorises the BCR to use the national social security
identiﬁcation number (SSIN) as the unique patient identiﬁcation.
This allows the Registry to perform accurate linkage procedures for
follow up on vital status and date of death and linkage with the
nomenclature of medical acts (diagnostic and therapeutic proce-
dures) and other clinical data [7].
This law also describes the role, objectives and data ﬂow of the
BCR. The data ﬂow must rely on clinical information from the
oncological care programmes in all hospitals (clinical network)
where speciﬁcally trained data managers extract cancer registra-
tion data from the medical ﬁles. They gather data concerning the
patient (SSIN, residence, sex, date of birth), tumour characteristics
(topography and morphology ICD-O-3 [8], clinical and pathological
TNM stage [9]) and treatment. Also the pathology laboratories are
required by law to supply the BCR with their data (pathology
network). Every (pre-) malignant specimen is encoded by a
pathologist, following international classiﬁcation guidelines (WHO
Classiﬁcation of Tumours [10], SNOMED [11]), and transferred to
the BCR accompanied by the report in full text.
An extended set of automated and manual validation proce-
dures based on the IARC guidelines [12] ensure validity and quality
of the data. The data source is consulted to provide additionalTable 1
Number of new diagnoses/deaths (N), crude rates (CR) and age standardised (using world
the mortality of chronic obstructive pulmonary disease (COPD) and chronic liver disea
Males 
N CR 
Incidence 2004–2010
Lung 38,481 105.9 
SCC/SCLC 18,279 50.3 
AC 12,078 33.2 
Oral cavity 2,977 8.2 
Pharynx 4,374 12.0 
Larynx 4,039 11.1 
Supraglottis 1,041 2.9 
Glottis 2,289 6.3 
Oesophagus 4,695 12.9 
SCC 2,214 6.1 
AC 2,266 6.2 
Liver 2,597 7.1 
HCC 2,015 5.5 
Cholangio 402 1.1 
Mortality 2004–2009
COPD 17,795 57.4 
CLD 5,122 16.5 
SCC: Squamous cell carcinoma.
SCLC: small cell lung cancer.
AC: Adenocarcinoma.
HCC: Hepatocellular carcinoma.details for cases with an uncertain diagnosis, insufﬁcient or
erroneous data or conﬂicting information.
The completeness was evaluated using the independent dataset
method. Record linkage with a dataset for rectal cancer for the
incidence years 2005 [1] and 2008 [2] resulted in an overlap of
98.6% and 99.6%, respectively. Linkage with the breast cancer
database from the national organised mammography screening
programme (incidence 2007–2010) resulted in a 99.5% overlap.
Similar results were obtained with one prospective clinical
registration project on head and neck cancer (100%) and two
non-overlapping projects for prostate cancer (RALP: Robot assisted
Laparoscopic Prostatectomy (99.9%) and brachytherapy (98.6%)).
Death certiﬁcates have only recently been made available
to the registry. A pilot study linking the mesothelioma death
statistics (2009–2010) showed that 416 out of 440 deaths (94.5%)
mentioned in the death certiﬁcates were also known by the
BCR. Death statistics do not contain the SSIN; hence the linking
process was based on a deterministic approach using a combina-
tion of patient identiﬁers (date of death, birth, sex and residence).
Further investigations are ongoing to trace back the remaining
5% and validate the diagnosis of mesothelioma. We estimate
the database of the BCR to be more than 95% complete,
incompleteness being more likely due to elderly patients with a
very poor prognosis at diagnosis and outpatients with a clinical
diagnosis only.
2.2. Study population
From the BCR database, incidence data for cancers of the oral
cavity (ICD10 [13]: C02.0–C05.0, C06), pharynx (ICD10: C01,
C05.1–C05.9, C09–C10, C12–C13), oesophagus (ICD10: C15), liver
(ICD10: C22), larynx (ICD10: C32), glottis (ICD10: C32.0),
supraglottis (ICD10: C32.1) and lung (ICD10: C34) are extracted
for the incidence years 2004–2010. Age standardised incidence
rates (using the World Standard Population (WSR)) are calculated
for every municipality (N = 589), the smallest administrative unit
in Belgium. For oesophageal, liver and lung cancer, incidence rates standard) rates (WSR) for the incidence of the selected cancers in 2004–2010 and for
se (CLD) in 2004–2009.
Females
WSR N CR WSR
57.7 12,894 34.0 18.8
27.1 4,249 11.2 6.1
19.1 5,844 15.4 8.8
5.3 1,263 3.3 1.9
7.9 1,266 3.3 2.1
6.7 610 1.6 1.0
1.8 232 0.6 0.4
3.7 246 0.6 0.4
7.6 1,638 4.3 2.0
3.8 1,042 2.8 1.4
3.5 498 1.3 0.5
4.2 1,172 3.1 1.5
3.2 702 1.9 0.9
0.6 330 0.9 0.4
25.2 9,558 29.6 8.8
10.4 3,049 9.4 5.0
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O-3 morphology codes [14].
Information on mortality for the years 2004–2009 was obtained
from the national Directorate-general Statistics and Economic
information (ADSEI) [15]. Municipality speciﬁc mortality rates
(WSR) were calculated for chronic liver disease (CLD; ICD10:
K70–K77) and chronic obstructive pulmonary disease (COPD;
ICD10: J40–J44).
Table 1 gives an overview of the incidence or mortality rates of
the selected diseases.
2.3. Mapping methodology
Incidence and mortality maps for Belgium were created using
the methodology developed at the Finnish Cancer Registry
[16,17]. The algorithm for this methodology was incorporated
into an in house developed software application of the BCR. The
geographic representations use municipality speciﬁc age standar-
dised rates (WSR). Cities with at least 80,000 inhabitants are
directly represented on the map as circles with a diameter relative
to the population size and a colour shading indicating the actual
calculated WSR in that city. The 19 municipalities of the Brussels
Capital Region (more than 1,000,000 inhabitants) were divided in
three separate circles. This division was based on socio-economic
parameters [2]. The socio-economic status is lowest in the
westernmost circle and highest in the easternmost circle.
Rates (WSR) from the remaining municipalities were smoothed.
For each grid (0.25 km2) on the map, a rate was calculated as a
weighted average of the WSR in all neighbouring municipalities
within 100 km from the centre of the grid. The weights were
inversely associated with the distance, the weight being halved atFig. 1. Age adjusted (WSR) mortality (2004–2009) of chronic liver disease (CLDa distance of 12 km. In addition, the weights were directly
proportional to the sizes of populations of the municipalities
within the radius of 100 km. A relative scale was applied. A change
in colour level corresponds to a 1.07 fold change in the WSR.
2.4. Statistical analyses
Poisson regression was applied to model the crude incidence
rate for the different cancer types versus the crude mortality rates
for CLD and COPD. Mortality for CLD was not included in the model
for lung cancer. Observed CLD and COPD crude rates in the same
municipality were taken as predictors. The municipality popula-
tion size was used as an offset in the Poisson models to model the
observed crude cancer rates. A negative binomial distribution for
the outcome incidence was assumed to allow for overdispersion.
Model assumptions were checked using plots of the standardised
deviance residuals and both the deviance and Pearson Chi-Square
statistics were considered as a measure of goodness-of-ﬁt. The
parameter estimates are reported as the expected multiplicative
change in mean crude rate (expressed per 100,000) for an increase
in the proxy crude rate of 10/100,000. No estimates are reported
when the model assumptions were not fulﬁlled. Statistical
modelling was performed with SAS version 9.3 (SAS Institute,
Cary, NC, USA.)
3. Results
Mortality rates for CLD and COPD were used as a proxy for the
prevalence of the use of alcohol and tobacco in Belgium,
respectively. The mortality rates for CLD are two- to threefold
higher in the southwest of Belgium than in the northeast (Fig. 1).) and chronic obstructive pulmonary disease (COPD) in Belgium, by sex.
Fig. 2. Age adjusted (WSR) mortality (2004–2009) of chronic obstructive pulmonary disease (COPD); and age adjusted (WSR) incidence (2004–2010) of total lung cancer,
small cell lung cancer (SCLC) and squamous cell carcinoma (SCC) and adenocarcinoma (AC) of lung, in Belgium, by sex.
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Fig. 3. Age adjusted (WSR) mortality (2004–2009) of chronic liver disease (CLD); and age adjusted (WSR) incidence (2004–2010) of cancers of oral cavity and pharynx in
Belgium, by sex.
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with the Netherlands towards the border with France in the
southwest of Belgium. Mortality rates for COPD increase twofold
from the coastal regions in the west–northwest of Belgium
towards the south and southeast of Belgium.
Incidence rates for male lung cancer increase slightly from the
west–northwest towards the south–southeast of Belgium (Fig. 2).
The gradient for male lung adenocarcinoma is less obvious and
higher rates are observed in the urban areas. For female lung
cancer there is a strong increasing trend from west to east for both
histological sub-types.
Cancers of the oral cavity and pharynx show a two- to threefold
increase in incidence from the northeast towards the southwest for
both sexes (Fig. 3). A similar pattern is observed for supraglottic
cancers of the larynx but not for glottic tumours (Fig. 4).Incidence rates for male oesophageal squamous cell carcinoma
(SCC) increase strongly from the northeast towards the southwest
(Fig. 5). The incidence rates for females show a similar pattern but with
more dominant urban incidence rates. The rates for adenocarcinoma
decrease from the northwest towards the southeast in both sexes.
Hepatocellular carcinoma (HCC) incidence in males increases
from the northeast towards the southwest (Fig. 6). The map for
female HCC indicates some urban dominance in incidence rates,
but no clear spatial trend is observed. The maps for cholangio-
carcinoma do not show a distinct trend in incidence rates and the
variation seen on the map may well be due to small numbers.
The scatterplot of oral cavity cancer incidence versus chronic
liver disease incidence is given in Fig. 7 as an illustration of the data
available for the Poisson regression analysis. Poisson regression
models for the crude cancer incidence rates versus the crude
Fig. 4. Age adjusted (WSR) mortality (2004–2009) of chronic liver diseases (CLD); and age adjusted (WSR) incidence (2004–2010) of laryngeal cancer, supraglottic cancer and
glottic cancer, by sex.
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Fig. 5. Age adjusted (WSR) mortality (2004–2009) of chronic liver diseases (CLD); and age adjusted (WSR) incidence (2004–2010) of oesophageal cancer, oesophageal
squamous cell carcinoma (SCC) and oesophageal adenocarcinoma (AC), by sex.
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Fig. 6. Age adjusted (WSR) mortality (2004–2009) of chronic liver diseases (CLD); and age adjusted (WSR) incidence (2004–2010) of liver cancer, hepatocellular carcinoma
(HCC) and cholangiocarcinoma, by sex.
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Fig. 7. Scatter plot of WSR incidence for oral cavity cancers versus chronic liver disease WSR mortality, each data point represents one municipality.
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visually observed from Figs. 2–6. The multiplicative increase in
the average cancer incidence rate is more than 30% per increase ofTable 2
Parameter estimates for the Poisson regression models for the crude cancer incidence 
obstructive pulmonary disease (COPD). Estimates on the intercept are not shown. The par
rate (per 100,000) for an increase in the proxy crude rate of 10/100,000.
Tumour type Males 
CLD COPD 
Estimate 95% CI Estimate 95% CI
Lung 1.05**** [1.04,1
SCC/SCLC 1.05**** [1.03,1
AC 1.05**** [1.03,1
Oral cavity 1.33**** [1.26,1.41] 1.02 [0.99, 1
Pharynx 1.35**** [1.29, 1.42] 1.05*** [1.02, 1
Larynx 1.14**** [1.09, 1.19] 1.04*** [1.02, 1
Supraglottis 1.13** [1.04, 1.24] 1.05* [1.00, 1
Glottis 1.04 [0.98, 1.10] 1.05*** [1.02, 1
Oesophagus 1.16**** [1.10, 1.21] 1.02 [0.99, 1
SCC 1.36**** [1.28, 1.44] 1.03 [0.99, 1
AC 0.98 [0.92, 1.05] 1.00 [0.96, 1
Liver 1.30**** [1.22, 1.37] 1.01 [0.98, 1
HCC 1.38**** [1.29, 1.47] 1.01 [0.97, 1
Cholangio –a –a
SCC: squamous cell carcinoma.
SCLC: small cell lung cancer.
AC: adenocarcinoma.
HCC: hepatocellular carcinoma.
a Model assumptions were not fulﬁlled.
**** p < .0001
*** p < .001
** p < .01
* p < .0510/100,000 in the municipality speciﬁc crude mortality rate of CLD
for cancers of the oral cavity and pharynx in both sexes, and for
SCC of the oesophagus and HCC in males (Table 2). There was arates versus the crude mortality rates of chronic liver diseases (CLD) and chronic
ameter estimates are expressed as the expected multiplicative change in mean crude
Females
CLD COPD
 Estimate 95% CI Estimate 95% CI
.06] 1.11**** [1.08, 1.14]
.06] 1.14**** [1.09, 1.18]
.07] 1.13**** [1.09, 1.17]
.05] 1.33**** [1.19, 1.48] 1.07* [1.00, 1.13]
.08] 1.34**** [1.19, 1.50] 1.09* [1.02, 1.16]
.07] –a –a
.10] –a –a
.09] –a –a
.05] 1.25**** [1.13, 1.37] 1.11*** [1.05,1.17]
.06] –a –a
.04] –a –a
.04] 1.15* [1.02, 1.31] 1.06 [0.99,1.14]
.04] –a –a
–a –a
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higher COPD mortality rates except for liver cancer. However,
these associations were not always consistent between the sexes.
4. Discussion
In this article, a geographical overview is presented of the
incidence rates in Belgium for cancers of the oral cavity, pharynx,
larynx, lung, oesophagus and liver; which all have a well-known
relation with alcohol and/or tobacco [18–22]. The data available
at the BCR enabled the creation of small-area based incidence
maps by histology for oesophageal, liver and lung cancer and by
sub-localisation for laryngeal cancer.
The National Health Surveys, based on small number of
participants [5] suggest that provinces in the southwest of Belgium
have a higher percentage of daily drinkers than the provinces in the
northeast. The proxy variables we used on the drinking and smoking
habits in Belgium demonstrate essentially the same pattern. Because
the high correlation between CLD and alcohol is well documented,
we believe that the mortality rate for CLD in a population group is a
reasonably good proxy for the prevalence of alcohol use.
We used the geographic distribution on COPD as the proxy
for tobacco smoking. Lung cancer, where the causal relationship
with tobacco was already established during the 1950s [23]
and the attributable fraction for smoking is higher than 80%, would
be another good proxy for smoking, and indeed the geographical
patterns for various histological types of lung cancer and COPD
mortality were similar. The Poisson regression models revealed
that increases in male and female COPD mortality rates were
signiﬁcantly associated with increasing incidence rates of lung
cancer. The visual similarity was least obvious for the incidence of
lung adenocarcinoma in men, which is in line with observations
that the association with tobacco is weaker for adenocarcinoma
than for the other histological types of lung cancer [23].
A strong visual similarity is observed between the maps for
cancers of the oral cavity and pharynx and the map for CLD. This
result is consistent with the known relation with alcohol for
these cancers [19,22]. The observed spatial patterns in Belgium,
with high rates close to the French border and much lower rates
close to the Dutch border, correspond well with the mortality
maps for these tumours published in the Atlas of Cancer
Mortality in the European Union [24], showing high mortality
rates for cancers of the oral cavity and pharynx in the north of
France and markedly lower rates in the Netherlands. The
regression models suggest that smoking also has a signiﬁcant
association on ecological level with these cancers but not
necessarily as strong as that for the drinking proxy.
The subsites of the larynx, glottis and supraglottis, show
different associations with different etiological factors. Due to their
anatomic location, the glottis is more highly exposed to inhaled
agents while the supraglottis is more exposed to ingested agents
[22]. The map for cancer of the supraglottis is more comparable
with alcohol prevalence, while the spatial pattern for glottic cancer
suggests higher analogy with the pattern of smoking.
Consumption of alcoholic beverages is known to be associated
with the risk for SCC of the oesophagus and only to a lesser degree
with the risk for oesophageal AC [22]. Our results indicate a rather
strong association between alcohol proxy and SCC but no
association at all with AC. The association between our proxy
for smoking and SCC was weak and for AC not existing. Hence,
other risk factors are involved in causation of oesophageal AC.
Multiple risk factors are suggested in the development of
oesophageal AC, including Barrett’s oesophagus, acid peptic
disorders and obesity [25–28]. Unfortunately, information onthe prevalence of these factors in different regions for Belgium is
not available.
The causal relation between the occurrence of malignant
tumours of the liver and consumption of alcoholic beverages was
some decades ago considered well-known [21] but more recent
ﬁndings of this issue are more controversial, suggesting more
complex associations, e.g., possible interaction with hepatitis B and
C. The liver can apparently handle alcohol in modest quantities but
not heavy intake [29]. This may be an explanation for our results
indicating a strong link between alcohol use and HCC in men but
not in women. Although alcohol is considered as a potential risk
factor for cholangiocarcinoma [30], no relation was observed with
the mortality rates for CLD.
5. Conclusion
Cancer incidence maps are an effective tool to visualise and
explore geographical differences and to seek for etiological
differences of, e.g., subtypes of a cancer. In oesophageal and
laryngeal cancer, two subtypes revealed different spatial patterns
and apparently with different causalities. This Belgian study is an
encouraging example of an approach how cancer registry data
can be used in the exploration of cancer aetiology and factors
behind regional cancer burden in circumstances where no long
historical time series of cancer data are available.
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